Coronavirus: Fosun Pharma, BioNTech’s China vaccine trial is an important step before securing marketing approval, companies say

China’s Shanghai Fosun Pharmaceutical Group and Germany’s BioNTech on Wednesday began clinical trial of its novel coronavirus vaccine candidate. The first 72 of 144 participants in mainland China received a dose of BNT162b1, according to a statement from the companies. “We are proud to be among the first international biopharmaceutical companies to initiate a clinical trial of a Covid-19 vaccine candidate in China as part of our effort to make our vaccine available globally, if approved,” said…

Read the original article at South China Morning Post